Thrombotic Thrombocytopenia Purpura (TTP): “Who Are You Calling a FAT RN?”
TTP is a type of thrombotic microangiopathy characterized by low platelets and evidence of a microangiopathic hemolytic anemia which produces platelet plugs and resultant red cell debris (called schistocytes). The underlying cause can be idiopathic or it can result from acquired antibodies to a protein called ADAMTS13 which serves to cleave von Willebrand multimers. TTP may also cause neurological abnormalities and less commonly renal failure. Definitive treatment is with plasmapheresis. It can cause a waxing and waning disease pattern. Untreated, the mortality is over 80%.
KeywordsTTP Thrombotic thrombocytopenia purpura Microangiopathic hemolytic anemia Thrombocytopenia Plasmapheresis Thrombotic microangiopathy
Joshua Faucher: No disclosures.
Colin Kaide: Callibra, Inc.-Discharge 123 medical software company. Medical Advisory Board Portola Pharmaceuticals. I have no relationship with a commercial company that has a direct financial interest in subject matter or materials discussed in article or with a company making a competing product.
- 2.Reese JA, Muthurajah DS, Hovinga JAK, Vesely SK, Terrell DR, George JN. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer. 2013;60:1676–82.CrossRefGoogle Scholar